Analystreport

Mersana Therapeutics Inc (NASDAQ: MRSN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.

Mersana Therapeutics, Inc.  (MRSN) 
Last mersana therapeutics, inc. earnings: 2/28 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: mersana.com/about-mersana